Lady that would be great. Thanks.

Legz, sorry to hear about the news. But glad to hear your doc is sticking with you on this.

hugs and prayers. Im sorry for your news.

I am also sorry to hear this. That just plain sucks!!! Sounds like you have a good neuro. Take care!

(((((Leggzz)))))

Sorry Leggz, hang in there we are all thinking of ya!
I know I am a newbie, but Ins. won't pay for ppms? I need to read more I guess. I'm confused anyway, but the way things have went for me, I'm afraid, that could be what they tell me. I have just steadily gotten worse. What is the Dr. diagnoses ppms, right off the bat? They won't try anything to help then?
Take care, thinking about ya!

Therw are no drugs approved to treat PPMS. Only the symtpoms, so once she writes it on the chart, the ins co will stop all DMDs and not cover anything that might help slow the progression of the disease. Which stinks. But then again none of them have worked so far.

I see... I remember when the doc, first thought I had fibro, back in the day they thought it was a fluke, she told me she wouldn't put that on the chart either, then I would be labeled. What a crock!! It's not like we don't want to get better!! Don't give up, keep on fighting!! We're all in this together!! Right everybody!!

Here is the information on the FDA Clinical Trial for pain and MS.

Duloxetine for Multiple Sclerosis Pain
This study is currently recruiting participants.
Verified by Eli Lilly and Company, March 2010

Keywords provided by Eli Lilly and Company:
Central Neuropathic Pain
Multiple Sclerosis


Purpose

This study is designed to primarily assess the efficacy and safety of duloxetine 60-120 mg once daily (QD)compared with placebo on the reduction of pain severity in patients with central neuropathic pain due to Multiple Sclerosis.

Detailed Description:

Study is a multicenter, randomized, double-blind, parallel, placebo-controlled, 20-week trial with 4 study periods. Patients who screen successfully (Study Period I) will be randomized in a 1:1 fashion to duloxetine 60 mg QD or placebo.

Starting with Study Period II, patients will be treated in a double-blind manner for 6 weeks. Patients who complete the 6-week, double-blind period will have the opportunity to participate in a 12-week, open-label, flexible-dose portion of the study (Study Period III).

Study Period IV is a taper phase designed to reduce the occurrence of discontinuation adverse events. Patients may enter Study Period IV at any time after Visit 3.

Legs, **There are 32 locations but you can ask your Neuro for other participating locations.**

For more information see FDA Clinical Trials below

http://clinicaltrials.gov/ct2/show/s...ow_locs=Y#locn


.